Melanoma complicating treatment with natalizumab for multiple sclerosis.
Mullen
John T
JT
Vartanian
Timothy K
TK
Atkins
Michael B
MB
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D039441:Integrin alpha4 / Q000276:immunology*; D008545:Melanoma / Q000139:chemically induced* / Q000276:immunology; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D019572:Retinal Neoplasms / Q000139:chemically induced*; D012878:Skin Neoplasms / Q000139:chemically induced*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D039441:Integrin alpha4